Sandoz Unveils $400m+ Investment In Slovenian Biosimilars Plant

Lendava Biologics Facility Is Expected To Become Fully Operational By 2026

 
• By David Wallace
  
Sandoz logo on building
Sandoz has unveiled plans to invest at least $400m in a biologics production facility in Slovenia • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Manufacturing

More from Business